Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Shows Genetic Links in ANCA-Associated Vasculitis

Lara C. Pullen, PhD  |  Issue: March 2019  |  March 19, 2019

Sarah2 / shutterstock.com

Sarah2 / shutterstock.com

CHICAGO—Ken Smith, MD, PhD, professor of medicine at the University of Cambridge, England, gave an update on anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) at the 2018 ACR/ARHP Annual Meeting.

Although vasculitis tends to be defined first by vessel size, the clinical differentiation between the forms is not reliable, explained Dr. Smith. For example, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are often treated as a single disease in clinical trials, but in truth they have different clinical features and two different autoantibody reactivities that correlate well, but not perfectly, with classification as GPA or MPA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Clinicians have long noticed that patients with AAV exhibited familial clustering, like that seen with rheumatoid arthritis (RA). These observations led to the identification of many candidate genes, and genome-wide association studies (GWAS) have allowed for the statistical association between disease and single nucleotide polymorphisms (SNPs). These results, published in 2012, confirmed that AAV has a genetic component.1

The researchers also found genetic distinctions between GPA and MPA that are more strongly associated with ANCA specificity than with the clinical syndrome and imply the response to the autoantigen proteinase 3 (PR3) is a central pathogenic feature of PR3-ANCA-associated vasculitis. This study that provided preliminary support for the hypothesis that PR3-ANCA-associated vasculitis and myeloperoxidase (MPO)-ANCA-associated vasculitis are distinct autoimmune syndromes.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

New Data

The recognition of the significant genetic contribution to AAV prompted a more detailed analysis, which yielded three main variants: HLA class II, SERPINA1 and PRTN3, each of which was specifically associated with PR3-ANCA.2 Both the HLA and non-HLA gene variants appear to alter proteins integral to immune responses that likely play key roles in the pathogenesis of AAV.

In particular, the largest effect on risk came from a triallellic HLA-DPB1 haplotype, meaning that three gene variants are inherited together. The resulting change in amino acid sequence affects a β-chain polymorphism in the HLA-DP antigen-binding pocket that modifies the protein’s peptide-binding properties and, therefore—possibly—T cell allorecognition. The analyses suggest there is only a single genetic association with the HLA region, and so the other SNPs identified in the region (e.g., collagen) are likely associated by virtue of linkage disequilibrium.

The two other loci related to AAV code for a serine protease inhibitor (serpin), which appears to control key intracellular and extracellular pathways of the auto-antigen PR3.3 New research suggests free PR3 may be more antigenic than complexed PR3, signifying that its role in autoimmunity may be more complicated than originally believed. These nuances can be further explored, because researchers published the genomic atlas of the human plasma proteome, which has expanded the ability to use specific proteins to link genetic factors to diseases.4 The evolving analyses support patient stratification based on ANCA specificity.

Researchers have used the accumulated data to determine why MPO- and PR3-AAV have so many clinical similarities. One hypothesis is that the various forms of ANCA have a common target (neutrophils) and the damage to the neutrophils results in a common clinical manifestation. “It could be a sort of antigenic accident,” explained Dr. Smith. If this is true, then it may be that the balance between costimulatory and coinhibitory signals shape T cell exhaustion and determine whether the immune system becomes autoreactive.5

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsVasculitis Tagged with:2018 ACR/ARHP Annual MeetingANCA-Associated Vasculitisanti-neutrophil cytoplasmic antibodies (ANCA)Churg-Strauss syndromeeosinophilic granulomatosis with polyangiitis (EGPA)

Related Articles
    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    July 13, 2016

    The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

    The Latest on Eosinophilic Granulomatosis with Polyangiitis

    July 19, 2018

    The past five years have been busier than usual for the Churg-Strauss syndrome. It was renamed eosinophilic granulomatosis with polyangiitis (EGPA).1 Longitudinal cohorts totaling 484 patients—approximately as many as all previous series combined—were described.2,3 A proposal was advanced to remove and rename a subset in which vasculitis may not be present.4 And shortly after the…

    ACR Winter Rheumatology Symposium: Tips for ANCA Testing

    May 1, 2013

    How to select the correct testing method and interpret conflicting results from antineutrophil cytoplasmic antibody tests

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences